Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.

PMID:
31530649
2.

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.

Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP.

Blood Cancer J. 2013 Apr 12;3:e109. doi: 10.1038/bcj.2013.6.

3.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR.

Cancer Res. 2011 Mar 1;71(5):1849-57. doi: 10.1158/0008-5472.CAN-10-3298. Epub 2011 Jan 13.

4.

eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BL, Stancato LF, Carter HW, Douglass LE, Carter JH.

Cancer Res. 2009 May 1;69(9):3866-73. doi: 10.1158/0008-5472.CAN-08-3472. Epub 2009 Apr 21.

5.

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG.

J Clin Invest. 2007 Sep;117(9):2638-48.

6.

A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity.

Schmidt RJ, Ficorilli JV, Zhang Y, Bramlett KS, Beyer TP, Borchert K, Dowless MS, Houck KA, Burris TP, Eacho PI, Liang G, Guo LW, Wilson WK, Michael LF, Cao G.

J Lipid Res. 2006 May;47(5):1037-44. Epub 2006 Jan 13.

7.

Cyclic AMP-independent activation of CYP3A4 gene expression by forskolin.

Dowless MS, Barbee JL, Borchert KM, Bocchinfuso WP, Houck KA.

Eur J Pharmacol. 2005 Apr 4;512(1):9-13.

PMID:
15814084
8.

A natural product ligand of the oxysterol receptor, liver X receptor.

Bramlett KS, Houck KA, Borchert KM, Dowless MS, Kulanthaivel P, Zhang Y, Beyer TP, Schmidt R, Thomas JS, Michael LF, Barr R, Montrose C, Eacho PI, Cao G, Burris TP.

J Pharmacol Exp Ther. 2003 Oct;307(1):291-6. Epub 2003 Jul 31.

PMID:
12893846
9.

Mechanisms of hypoxic vasodilation in ferret pulmonary arteries.

Wiener CM, Banta MR, Dowless MS, Flavahan NA, Sylvester JT.

Am J Physiol. 1995 Sep;269(3 Pt 1):L351-7.

PMID:
7573469

Supplemental Content

Loading ...
Support Center